Uroxatral Tablet, Extended Release
Product Images NDC 59212-200

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Uroxatral (NDC 59212-200). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Advanz Pharma (us) Corp., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Bottle 100tablets

Label for Uroxatral alfuzosin HCl 10 mg extended-release tablets by Advanz Pharma (US) Corp. The label includes dosage instructions to swallow tablets whole without chewing or crushing, contains 100 tablets, and bears the NDC 59212-200-10. Additional information includes manufacturer and distributor details, storage instructions, and barcodes.*

FDA Label Image

Bottle 30tablets

Label for Uroxatral alfuzosin HCl 10 mg extended-release tablets. The label includes instructions to swallow tablets whole without chewing or crushing. It shows the product quantity as 30 tablets and indicates prescription-only use. Manufactured by Concordia Pharmaceuticals and distributed by Advanz Pharma (US) Corp. The label includes barcode, lot, and expiration placeholders.*

FDA Label Image

Chemical Structure (Image 01)

Chemical structure of Alfuzosin hydrochloride (Alfuzosin HCl), the active ingredient in Uroxatral. The diagram displays the molecule's atoms and bonds in a line-angle format, including the aromatic rings, amine groups, and hydrochloride component.*

FDA Label Image

Figure 1 (Image 02)

A line graph depicting Alfuzosin plasma concentration (ng/mL) over 24 hours, comparing two conditions: FED and FASTED. The graph shows higher plasma concentrations under FED conditions with peak levels between 8 to 10 hours, while FASTED conditions exhibit lower and steadier concentrations throughout the time period.*

FDA Label Image

Figure 2 (Image 03)

A line graph comparing mean change over days of treatment (0, 28, 56, 84) between Uroxatral (Alfuzosin HCl extended-release tablets) and placebo groups. The Uroxatral group shows a greater mean reduction over time, with a significant difference indicated at day 84 (p < 0.001). The x-axis represents days of treatment and the y-axis represents mean change.*

FDA Label Image

Figure 3 (Image 04)

A line graph comparing the mean change over days of treatment (0, 28, 56, 84) between placebo and Uroxatral (alfuzosin HCl) groups. The graph shows a greater reduction in mean change for Uroxatral compared to placebo, with statistical significance indicated at day 84 (p < 0.01).*

FDA Label Image

Figure 4 (Image 05)

A line graph comparing the mean change in a parameter over 84 days of treatment between two groups: placebo (N=150) and Uroxatral (N=151). The x-axis represents days of treatment (0, 28, 56, 84), and the y-axis shows mean change values. Data points indicate a greater decrease for the Uroxatral group compared to placebo, with a statistical significance marker (p < 0.01) shown on day 84.*

FDA Label Image

Figure 5 (Image 06)

A line graph showing mean change in mL/s over days of treatment (0, 28, 56, 84) comparing Uroxatral (Alfuzosin HCl) versus placebo. Uroxatral demonstrates a higher mean change maintained from day 28 through day 84 compared to placebo. A statistical significance indicator (*** p < 0.001) appears on the graph.*

FDA Label Image

Figure 6 (Image 07)

A line graph charting mean change in mL/s over days of treatment (0 to 84) comparing Uroxatral (Alfuzosin HCl extended-release tablets) to placebo. The graph includes data points at days 0, 14, 28, 56, and 84, showing higher mean change for Uroxatral throughout, with statistical significance noted at day 84 (p < 0.05).*

FDA Label Image

Figure 7 (Image 08)

A line graph comparing the mean change in mL/s over days of treatment (0 to 84 days) between Uroxatral (N=151) and placebo (N=150). The graph shows higher mean change values for Uroxatral across the time points, with non-significant difference (NS p > 0.05) indicated at the bottom.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.